Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating Costs and Expenses:
General and administrative	$ 1,655,000	$ 1,419,000
Research and development	2,597,000	1,118,000
Total Operating Costs and Expenses	4,252,000	2,537,000
Loss from Operations	(4,252,000)	(2,537,000)
Other Expense:
Exchange loss	(23,000)	0
Interest income	2,000	0
Total Other Expense	(21,000)	0
Net Loss	(4,273,000)	(2,537,000)
Net Loss Attributable to Non-controlling Interest	0	(1,000)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	(4,273,000)	(2,536,000)
Effect of Series A Preferred Stock Price adjustment	0	(7,402,000)
Net Loss Attributable to Common Stockholders	$ (4,273,000)	$ (11,459,000)
Net Loss Per Share - Basic	$ (0.03)	$ (0.13)
Net Loss Per Share - Dilutive	$ (0.03)	$ (0.13)
Weighted average number of shares outstanding during the period - basic	138,201,442	90,807,693
Weighted average number of shares outstanding during the period - dilutive	138,201,442	90,807,693
Series A Preferred Stock [Member]
Other Expense:
Preferred Stock Dividends, Income Statement Impact	$ 0	$ (24,000)
Effect of Series A Preferred Stock Price adjustment	0	(7,402,000)
Series B Preferred Stock [Member]
Other Expense:
Net Loss Attributable to Non-controlling Interest		100,000
Preferred Stock Dividends, Income Statement Impact	0	(1,497,000)
Net Loss Attributable to Common Stockholders		(11,500,000)
Preferred Stock [Member] | Series B Preferred Stock [Member]
Other Expense:
Net Loss Attributable to Non-controlling Interest		0
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	$ 0	$ 0